Pb2099: a first-in-human phase 1 trial of nx-1607, a first-in-class oral cbl-b inhibitor, in patients with advanced malignancies including richter transformation dlbcl
HemaSphere(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
HemaSphere(2022)